Maintenance and interruption of CAMZYOS (mavacamten)

BSE guidance supports streamlined echo monitoring

The British Society of Echocardiography (BSE) recommends a full comprehensive echocardiographic assessment (standard echocardiography) before starting treatment with CAMZYOS, and a targeted echocardiography protocol thereafter to improve efficiency for services and patients treated with CAMZYOS.¹

A standard echocardiography involves a full transthoracic study, including structure and function assessment of the left ventricle, mitral valve behaviour and LVOT gradients. A full assessment is needed to confirm a HCM diagnosis and inform treatment decision-making.^1,2

During treatment, repeat echocardiography is advised because a reduction in LVEF has been observed in a small number of patients receiving CAMZYOS.^1,2 The BSE guidance recommends a targeted monitoring approach during treatment to support reproducibility and reduce the time needed for each surveillance scan while still meeting monitoring requirements.¹

A targeted echocardiography is a focused assessment designed to record only the measurements needed for safe monitoring of patients on CAMZYOS. These include LVEF, LVOT gradients at rest and with Valsalva, systolic anterior motion assessment and mitral regurgitation severity.¹

The BSE recommends a minimum 45 minute slot for routine non complex outpatient scans. Targeted scans may take less time, but the BSE does not give timings for these. The time needed depends on patient complexity, workflow, and staffing.³

The monitoring schedule is based on individuals with LVEF ≥55% and Valsalva LVOT gradient <30 mmHg who require echocardiography at Week 4, Week 8 and Week 12 after CAMZYOS initiation, then every 6 months thereafter.^1,2 See the full monitoring schedule below.

CAMZYOS treatment maintenance allows for regular assessment of treatment goals²

Treatment with CAMZYOS should be interrupted at any clinic visit if LVEF <50%²

BSE, British Society of Echocardiography; echo, echocardiography; HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract.

References

Culshaw CM et al. Echo Res Pract. 2025;12(1):15.
CAMZYOS (mavacamten) Summary of Product Characteristics.
British Society of Echocardiography. Position statement: Recommendations for time-slots for echocardiography. 2024. Available at: https://www.bsecho.org/Public/Resources/Clinical-guidance/202401-PUD007.aspx. Date accessed: December 2025.

3500-GB-2500228 | December 2025

BSE guidance supports streamlined echo monitoring

The British Society of Echocardiography (BSE) recommends a full comprehensive echocardiographic assessment (standard echocardiography) before starting treatment with CAMZYOS, and a targeted echocardiography protocol thereafter to improve efficiency for services and patients treated with CAMZYOS.1

The BSE recommends a minimum 45 minute slot for routine non complex outpatient scans. Targeted scans may take less time, but the BSE does not give timings for these. The time needed depends on patient complexity, workflow, and staffing.3

The monitoring schedule is based on individuals with LVEF ≥55% and Valsalva LVOT gradient <30 mmHg who require echocardiography at Week 4, Week 8 and Week 12 after CAMZYOS initiation, then every 6 months thereafter.1,2 See the full monitoring schedule below.

References

The British Society of Echocardiography (BSE) recommends a full comprehensive echocardiographic assessment (standard echocardiography) before starting treatment with CAMZYOS, and a targeted echocardiography protocol thereafter to improve efficiency for services and patients treated with CAMZYOS.¹

The BSE recommends a minimum 45 minute slot for routine non complex outpatient scans. Targeted scans may take less time, but the BSE does not give timings for these. The time needed depends on patient complexity, workflow, and staffing.³

The monitoring schedule is based on individuals with LVEF ≥55% and Valsalva LVOT gradient <30 mmHg who require echocardiography at Week 4, Week 8 and Week 12 after CAMZYOS initiation, then every 6 months thereafter.^1,2 See the full monitoring schedule below.